Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The panorama of somatic mutations in toddler MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47:330–7.
Aoki Y, Watanabe T, Saito Y, Kuroki Y, Hijikata A, Takagi M, et al. Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. Blood. 2015;125:967–80.
Burmeister T, Meyer C, Schwartz S, Hofmann J, Molkentin M, Kowarz E, et al. The MLL recombinome of grownup CD10-negative B-cell precursor acute lymphoblastic leukemia: outcomes from the GMALL examine group. Blood. 2009;113:4011–5.
Gökbuget N, Stelljes M, Viardot A, Nachtkamp Okay, Steffen B, Schneller F, et al. First outcomes of the risk-adapted, MRD-stratified GMALL trial 08/2013 in 705 adults with newly recognized acute lymphoblastic leukemia/lymphoma (ALL/LBL). Blood. 2021;138:362.
Beldjord Okay, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, et al. Oncogenetics and minimal residual illness are impartial end result predictors in grownup sufferers with acute lymphoblastic leukemia. Blood. 2014;123:3739–49.
van Dongen JJ, van der Velden VH, Brüggemann M, Orfao A. Minimal residual illness diagnostics in acute lymphoblastic leukemia: want for delicate, quick, and standardized applied sciences. Blood. 2015;125:3996–4009.
Gökbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, et al. Grownup sufferers with acute lymphoblastic leukemia and molecular failure show a poor prognosis and are candidates for stem cell transplantation and focused therapies. Blood. 2012;120:1868–76.
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved threat classification for risk-specific remedy based mostly on the molecular examine of minimal residual illness (MRD) in grownup acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–62.
van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, et al. Prognostic significance of minimal residual illness in infants with acute lymphoblastic leukemia handled inside the Interfant-99 protocol. Leukemia. 2009;23:1073–9.
Burmeister T, Marschalek R, Schneider B, Meyer C, Gökbuget N, Schwartz S, et al. Monitoring minimal residual illness by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia. 2006;20:451–7.
Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J, et al. Medical significance of minimal residual illness quantification in grownup sufferers with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116–23.
van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grümayer ER, et al. Evaluation of minimal residual illness by Ig/TCR gene rearrangements: pointers for interpretation of real-time quantitative PCR information. Leukemia. 2007;21:604–11.
Stutterheim J, van der Sluis IM, de Lorenzo P, Alten J, Ancliffe P, Attarbaschi A, et al. Medical implications of minimal residual illness detection in infants with KMT2A-rearranged acute lymphoblastic leukemia handled on the interfant-06 protocol. J Clin Oncol. 2021;39:652–62.
Gökbuget N. MRD in grownup Ph/BCR-ABL-negative ALL: how greatest to eradicate? Hematology Am Soc Hematol Educ Program. 2021;2021:718–25.
Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, et al. Genetic alterations and MRD refine threat evaluation for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL examine. Blood. 2023;142:1806–17.
